The inhalation company Inhalation Sciences reports sharply higher revenue and order intake in the first quarter compared with the same period the previous year. Operating loss also decreased. The company is still looking for a buyer. Net sales rose to SEK 4.1 million (0.8). Order intake increased to SEK 2.4 million (0.9).Operating profit improved to SEK -1.4 million (-2.2). Net profit amounted to SEK -1.4 million (-2.2). Earnings per share improved to SEK -0.04 (-0.15).CEO Manoush Masarrat states that the high revenue during the quarter was mainly driven by the large order backlog built up during the fourth quarter of 2025. The company also continued to convert its pipeline into formal orders.The company further states that the process of finding possible buyers for the business continues together with adviser Pharmaventures, with the ambition to complete the process before summer 2026."In parallel with this, we continue to work through our pipeline in the form of existing and new potential customers and we see continued strong interest in our unique technology and our various modules", he writes. Key figuresQ1 2026Q1 2025ChangeOrder intake2.40.9166.7%Revenue4.10.8412.5%Operating profit-1.4-2.236.4%Net profit-1.4-2.236.4%Earnings per share-0.04-0.1573.3%